Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives $358.50 Consensus Target Price from Brokerages
Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report) has been given a consensus recommendation of “Hold” by the six ratings firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. […]
23 Mar 09:35 · The Markets Daily